Telehealth firms shape access to costly obesity drugs for insurance coverage

Telehealth companies are navigating a complex landscape as they support patients using new obesity drugs. These companies provide crucial lifestyle coaching and monitoring to help individuals achieve weight loss goals with medications like Ozempic and Wegovy. However, they also face demands from employers and insurers to control the high costs associated with these treatments.

This dual role places telehealth providers in a challenging position. They aim to maximize patient success by ensuring adherence and managing side effects, which often requires ongoing support. Simultaneously, they must operate within budgets set by employers who are concerned about the escalating expenses of these popular drugs. This creates a delicate balance between patient care and financial oversight.

The companies' ability to influence spending on obesity drugs is significant. They can potentially steer patients toward more cost-effective options or implement stricter protocols for prescribing and refilling medications. This influence underscores the growing importance of telehealth in managing chronic conditions and the ongoing debate about how to make expensive new therapies accessible and sustainable.